A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

NCT06962787 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cancer

Interventions

DRUG: BL-B01D1
DRUG: Axitinib
DRUG: Lenvatinib
DRUG: Pembrolizumab

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]